Literature DB >> 1685926

Prevalence of hepatitis C virus antibody in an area endemic for hepatitis B virus and human T cell leukaemia virus.

S Ochi1, M Onji, K Shiraishi, K Ohtu, T Akao, Y Yano, N Takei, H Matsui, Y Ohta, M Umeda.   

Abstract

To clarify the prevalence of concurrent infection with hepatitis C virus (HCV), hepatitis B virus (HBV) and human T cell leukaemia virus (HTLV), we measured HCV antibody in the population of a district endemic for HBV and HTLV infection. Blood samples were collected in June 1990 from 579 inhabitants of four islands of Uwa Bay in the southwest of Ehime Prefecture in Japan. Anti-HCV antibody against C100-3 protein was detected using an enzyme-linked immunosorbent assay kit (Ortho Diagnostics). Thirteen of the 579 inhabitants (2.2%) were positive for anti-HCV, and this prevalence rate was not significantly different from the frequency of anti-HCV in Tokyo blood donors. A total of 11% (64 of 579) of the subjects were positive for HBsAg and 3.3% (19 of 579) were positive for anti-HTLV. These frequencies of HBsAg and anti-HTLV positivity were distinctly higher than the respective means of Japanese. All anti-HCV positive individuals were negative for HBsAg and anti-HTLV, while 54% (7 of 13) had increased alanine aminotransferase levels. These data suggest that the prevalence of HCV infection is not high even in an area endemic for HBV and HTLV infection.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1685926     DOI: 10.1111/j.1440-1746.1991.tb00918.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  1 in total

1.  Surveillance of Hepatitis Viruses in Several Small Islands of Japan by Ship: A Public Health Approach for Elimination of Hepatitis Viruses by 2030.

Authors:  Tomohiro Akao; Morikazu Onji; Keitarou Kawasaki; Takahide Uehara; Yukima Kuwabara; Takashi Nishimoto; Shinji Yamamoto; Jiro Miyaike; Masaki Oomoto; Teruki Miyake
Journal:  Euroasian J Hepatogastroenterol       Date:  2019 Jul-Dec
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.